A swarm of top biotech ex­ecs protest against Trump’s trav­el ban, say­ing it threat­ens the en­tire in­dus­try

The re­ac­tion against Pres­i­dent Trump’s de­ci­sion to ban trav­el from 7 pre­dom­i­nant­ly Mus­lim na­tions drew an in­stant re­ac­tion from the biotech world, gain­ing a quick thumbs-down from a large ma­jor­i­ty of the hun­dreds of in­dus­try ex­ec­u­tives we’ve been in touch with.

Now the biotech op­po­si­tion is get­ting or­ga­nized.

In a let­ter pub­lished in Na­ture Biotech­nol­o­gy this morn­ing, 166 biotech ex­ecs lev­eled a blast at Trump’s trav­el ban, now stayed at least tem­porar­i­ly by a court rul­ing, say­ing that it strikes at the heart of the in­dus­try’s abil­i­ty to re­cruit the best and bright­est staff from all over the world while rais­ing deep seat­ed fears among all their staffers from out­side the US.

The let­ter was signed by a long line­up of high-pro­file ex­ec­u­tives drawn from the CEO suite, ven­ture cap­i­tal and acad­e­mia, in­clud­ing Herve Hop­penot, the French CEO of Delaware-based In­cyte, George Scan­gos, the for­mer Bio­gen CEO who’s now lead­ing a start­up, and MIT’s Bob Langer, a se­r­i­al biotech en­tre­pre­neur with more than 30 star­tups to his cred­it.

“If this mis­guid­ed pol­i­cy is not re­versed,” they say, “Amer­i­ca is at risk of los­ing its lead­er­ship po­si­tion in one of its most im­por­tant sec­tors, one that will shape the world in the twen­ty-first cen­tu­ry.”

The let­ter un­der­scores the groundswell of op­po­si­tion in the in­dus­try to the ban. It al­so high­lights a grow­ing di­vide be­tween the ex­ec­u­tives who lead this field and BIO, the in­dus­try or­ga­ni­za­tion which lob­bies on their be­half. So far BIO has stayed mum about the trav­el ban.

(Ed­i­tor’s note: Late on Tues­day I re­ceived the fol­low­ing state­ment from BIO Chair Ron Co­hen and three board mem­bers, Je­re­my Levin, John Maraganore and Paul Hast­ings, tak­ing ex­cep­tion to that re­mark about BIO.

“We did want to high­light an in­ac­cu­ra­cy in your re­port re­gard­ing spec­u­la­tion that the let­ter re­flects a “grow­ing rift” be­tween BIO and its CEO and com­pa­ny mem­bers. There is no such rift, grow­ing or oth­er­wise; we are choos­ing to speak out on the ban as in­dus­try lead­ers, not as a trade as­so­ci­a­tion. This is not dis­sim­i­lar to how tech in­dus­try CEOs, not their trade as­so­ci­a­tion, have spo­ken out on this mat­ter. In­deed, we be­lieve that BIO is an es­sen­tial or­ga­ni­za­tion for the well-be­ing of our in­dus­try, which is why we all de­vote con­sid­er­able time out of our busy sched­ules to its ac­tiv­i­ties.”

My re­ply: Si­lence is a po­si­tion, and it’s marked­ly dif­fer­ent from what ex­ecs, in­clud­ing these board mem­bers, have ex­pressed.)

Most of the top CEOs of the Big Phar­ma com­pa­nies, many of whom have been lob­by­ing for tax re­form that would al­low them to repa­tri­ate bil­lions of dol­lars in re­serves held over­seas, have al­so stayed qui­et on this is­sue. But there was at least one ex­cep­tion to the Big Phar­ma rule of si­lence — aside from Al­ler­gan CEO Brent Saun­ders.

“Sci­ence doesn’t have any bor­ders, so any­thing that gets in the way of a bor­der­less sci­ence ex­change doesn’t help,” said As­traZeneca CEO Pas­cal So­ri­ot, quot­ed to­day by Bloomberg. The UK-based phar­ma gi­ant has re­search and man­u­fac­tur­ing sites in Mass­a­chu­setts and Mary­land. “We want to be able to move our peo­ple and our sci­en­tists around the world.”

The Bloomberg sto­ry al­so rais­es con­cerns that the Trump ad­min­is­tra­tion’s fo­cus on the H-1B visa pro­gram used to bring in sci­en­tists from around the world could be al­tered, mak­ing it hard­er to re­cruit abroad.

Here’s a por­tion of the let­ter:

The Unit­ed States has led the world in med­i­cine pro­duc­tion for decades, not on­ly be­cause of its abil­i­ty to fi­nance drug dis­cov­ery, but al­so be­cause, more than any oth­er coun­try, the Unit­ed States rep­re­sents op­por­tu­ni­ty re­gard­less of bor­ders, gen­der, race, sex­u­al ori­en­ta­tion or po­lit­i­cal cast. This has en­abled our in­dus­try to at­tract the best tal­ent, wher­ev­er it is found. This as­pect of our in­dus­try is a core rea­son the Unit­ed States has built its unique strength in bio­phar­ma­ceu­ti­cals.

At a stroke, the new ad­min­is­tra­tion has com­pro­mised years of in­vest­ment in this na­tion­al trea­sure. Our col­leagues who are here on visas or are in glob­al out­posts are now fear­ful and un­cer­tain of their sta­tus. Sci­en­tists based in oth­er coun­tries and em­ployed by our com­pa­nies are afraid to come to the Unit­ed States or are can­cel­ing trips. The par­ents and fam­i­lies of im­mi­grants who live and work in the Unit­ed States are re­luc­tant to at­tempt to trav­el to and from the US.

Though the ban from the Trump ad­min­is­tra­tion is aimed at sev­en coun­tries, our glob­al em­ploy­ees in­ter­pret the un­der­ly­ing mes­sage as, “Amer­i­ca is no longer wel­com­ing of any im­mi­grants, what­so­ev­er.” They fear sim­i­lar or­ders could be is­sued for oth­er coun­tries at a mo­ment’s no­tice. They fear be­ing stig­ma­tized and dis­crim­i­nat­ed against, sim­ply be­cause of their re­li­gion, ir­re­spec­tive of the na­tion they come from. Sev­er­al among us have heard from em­ploy­ees about their de­por­ta­tion fears, how they do not feel com­fort­able leav­ing the coun­try on busi­ness or how they now feel cut off from their fam­i­ly abroad.

Every na­tion has the right to de­ter­mine who comes across its bor­ders. Every na­tion needs to be vig­i­lant in de­fend­ing it­self against and hunt­ing down ter­ror­ists. The ac­tions tak­en by the Trump ad­min­is­tra­tion, how­ev­er, were poor­ly con­ceived and im­ple­ment­ed; they have raised deep fears and con­cerns across the biotech in­dus­try, in which di­ver­si­ty and the free flow of ideas and peo­ple have cre­at­ed an Amer­i­can pow­er­house of med­i­cine. 

If this mis­guid­ed pol­i­cy is not re­versed, Amer­i­ca is at risk of los­ing its lead­er­ship po­si­tion in one of its most im­por­tant sec­tors, one that will shape the world in the twen­ty-first cen­tu­ry. In­deed, it will harm an in­dus­try dom­i­nat­ed by small­er com­pa­nies and star­tups, the very kind of in­dus­try the ad­min­is­tra­tion has said it wants to sup­port. It will slow the fight against the many dis­eases that af­flict us, as well as car­ry neg­a­tive eco­nom­ic con­se­quences for the Unit­ed States.

You can find a PDF with the list of ex­ec­u­tives who signed the let­ter here: Im­mi­gra­tion Let­ter Sig­na­tures

A new era of treat­ment: How bio­mark­ers are chang­ing the way we think about can­cer

AJ Patel was recovering from a complicated brain surgery when his oncologist burst into the hospital room yelling, “I’ve got some really great news for you!”

For two years, Patel had been going from doctor to doctor trying to diagnose his wheezing, only to be dealt the devastating news that he had stage IV lung cancer and only six months to live. And then they found the brain tumors.

“What are you talking about?” Patel asked. He had never seen an oncologist so happy.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

David Ricks, Eli Lilly CEO (David Paul Morris/Bloomberg via Getty Images)

Eli Lil­ly set to in­vest $2.1B in home state man­u­fac­tur­ing boost

Eli Lilly is looking to expand its footprint in its home Hoosier State by making a major investment in manufacturing.

The pharma is investing $2.1 billion in two new manufacturing sites at Indiana’s LEAP Lebanon Innovation and Research District in Boone County, northwest of Lilly’s headquarters in Indianapolis.

The two new facilities will expand Lilly’s manufacturing network for active ingredients and new therapeutic modalities, including genetic medicines, according to a press release.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

Pfiz­er and CD­MOs ramp up Paxlovid man­u­fac­tur­ing with Kala­ma­zoo plant ex­pan­sion lead­ing the way

As the Covid-19 pandemic continues to evolve, pharma companies and manufacturers are exploring how to step up production on antivirals.

Pfizer is planning to expand its Kalamazoo-area facility to increase manufacturing capabilities for the oral Covid-19 antiviral Paxlovid, according to a report from Michigan-based news site MLive. The expansion of the facility, which serves as Pfizer’s largest manufacturing location, is expected to create hundreds of “high-skilled” STEM jobs, MLive reported. No details about the project’s cost and timeline have been released, but according to MLive, Pfizer will announce the details of the expansion at some point in early June.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

FDA spells out the rules and re­stric­tions for states seek­ing to im­port drugs from Cana­da

The FDA is offering more of an explanation of the guardrails around its program that may soon allow states to import prescription drugs in some select circumstances from Canada, but only if such imports will result in significant cost reductions for consumers.

While the agency has yet to sign off on any of the 5 state plans in the works so far, and PhRMA’s suit to block the Trump-era rule allowing such imports is stalled, the new Q&A guidance spells out the various restrictions that states will have to abide by, potentially signaling that a state approval is coming.

Pfizer CEO Albert Bourla at the World Economic Forum (Gian Ehrenzeller/Keystone via AP Images)

All about ac­cess: Pfiz­er moves to a non-prof­it mod­el for drug sales in 45 low­er-in­come coun­tries

Leading the way to increase access to cheaper drugs worldwide, Pfizer said Wednesday it will provide all current and future patent-protected medicines and vaccines available in the US or EU on a not-for-profit basis to about 1.2 billion people in 45 lower-income countries.

Rwanda, Ghana, Malawi, Senegal and Uganda are the first five countries to sign on to this accord, which will also seek to blaze new paths for quick and efficient regulatory and procurement processes to reduce the usual delays in making new medicines and vaccines available in these countries.

US sees spike in Paxlovid us­age as Mer­ck­'s mol­nupi­ravir and As­traZeneca's Evusheld are slow­er off the shelf

New data from HHS show that more than 162,000 courses of Pfizer’s Covid-19 antiviral Paxlovid were administered across the US over the past week, continuing a streak of increased usage of the pill, and signaling not only rising case numbers but more awareness of how to access it.

In comparison to this week, about 670,000 courses of the Pfizer pill have been administered across the first five months since Paxlovid has been on the US market, averaging about 33,000 courses administered per week in that time.

Te­va, Al­ler­gan reach yet an­oth­er opi­oid set­tle­ment — ef­fec­tive­ly end­ing WV tri­al

Teva and Allergan have reached settlements with multiple states over their involvement in the opioid crisis. Their latest is worth 9 figures.

West Virginia attorney general Patrick Morrisey announced the newest settlement, worth $161.5 million, at a press conference on Wednesday. The deal would resolve claims that the companies helped fuel the state’s opioid epidemic. If it goes through, it could become the largest state-negotiated settlement in West Virginia’s history, according to Reuters.

Roche un­veils three new mon­key­pox tests as cas­es rise

Health experts maintain that the current monkeypox situation is a stark contrast to Covid. Even so, a handful of biotechs have sprung to action, including Roche, who quickly developed a set of three tests to detect the virus.

Roche and subsidiary TIB Molbiol unveiled their Lightmix Modular Virus test kits on Wednesday — three unique test kits that can help track the spread of monkeypox.

The first kit detects orthopoxviruses, including all monkeypox viruses originating from the West African and Central African forms of the virus. The second kit is a specific test that detects monkeypox viruses only, while the third simultaneously tests for both orthopoxviruses and monkeypox viruses.

New law­suit ac­cus­es GSK of 'de­vice hop­ping' to block gener­ic in­haler com­pe­ti­tion

Despite inhalers being on the market for decades, many patients still can’t afford them. A new lawsuit filed in Missouri federal court puts the blame on GSK.

Last week, plaintiff Elliot Conrad Dale — who’s paid for GSK’s Ventolin and Arnuity Ellipta inhalers — filed a class-action lawsuit against the pharma giant, accusing it of scheming to block generic versions of its brand-name inhalers.